HCV Triple Therapy Regimen to Suppress Viral Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis C virus (HCV) infection, particularly those involving interferon alfa and ribavirin, have limited efficacy and are associated with significant side effects, and there is a need for alternative treatments to address viral resistance and treatment non-responsiveness.
Innovation Solution
A therapeutic combination of Compound (1), a selective HCV NS3 serine protease inhibitor, with interferon alfa and ribavirin, administered using regimens such as a lead-in period and loading dose to achieve higher blood levels of interferon alpha and ribavirin, thereby suppressing viral resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon alfa and ribavirin combination therapy is used to treat HCV infection, then antiviral response is achieved, but significant side effects occur and viral resistance emerges
Solution Approach 1:
The patent combines three agents (Compound 1, interferon alfa, and ribavirin) into a triple combination therapy regimen. This merging of multiple therapeutic agents with different mechanisms of action synergistically enhances antiviral response while suppressing viral resistance and reducing side effects compared to interferon-ribavirin alone.
Solution Approach 2:
The patent implements specific dosage parameters including a lead-in period of interferon-ribavirin therapy followed by the addition of Compound 1, and employs loading doses (2x standard dose) of Compound 1 on days 1-3. These parameter changes optimize pharmacokinetic profiles and viral suppression while managing toxicity.
2Device complexity
If standard interferon-ribavirin combination therapy is administered, then treatment is simplified, but virologic response rate remains at or below 50%
Solution Approach 1:
The patent merges Compound 1 (a potent HCV NS3 protease inhibitor) with interferon alfa and ribavirin into a triple combination therapy. This combination achieves virologic response rates exceeding 50% in treatment-naive patients and improves response in treatment-experienced patients, overcoming the limited efficacy of interferon-ribavirin alone.
3Speed
If Compound (1) monotherapy is administered, then rapid antiviral effect is observed, but viral resistance forms after 5-6 days
Solution Approach 1:
The patent implements a lead-in period where interferon alfa and ribavirin are administered for 2-4 days before adding Compound 1. This preliminary action establishes initial viral suppression and immune modulation, creating a more favorable environment that prevents rapid resistance formation when Compound 1 is introduced.
Solution Approach 2:
The patent applies different dosing strategies at different time points: loading doses (2x standard dose) of Compound 1 are administered on days 1-3, followed by standard dosing. This temporal variation in dosing intensity creates optimal pharmacokinetic profiles that maintain viral suppression while reducing selective pressure for resistance.
Data Source
AI summary
The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin and particular regimens for administering this combination. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient.